Am J Hematol

1. GILBERT JS, Connor M, Bosma G, Zhang J, et al
   Known Prognostic Models Fail to Predict Outcomes for Venetoclax and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia: A Single-Center Retrospective Analysis.
   Am J Hematol. 2025 Aug 14. doi: 10.1002/ajh.70034.
   

   >> Share

   
   

   
   Ann Hematol

2. GAO Q, Chen Y, Le S, Li N, et al
   Clinical characteristics and outcome of pediatric patients with high-risk acute promyelocytic leukemia, with special focus on risk factors of early death.
   Ann Hematol. 2025 Aug 12. doi: 10.1007/s00277-025-06528.
   

   >> Share

   
   

   
   Blood

3. MONTEFIORI LE, Iacobucci I, Gao Q, Moore J, et al
   Venetoclax plus gilteritinib is effective in preclinical models of FLT3-mutant BCL11B-a lineage-ambiguous leukemia.
   Blood. 2025 Aug 14:blood.2025028985. doi: 10.1182/blood.2025028985.
   

   >> Share

   
   
4. ZHOU X, Chen J, Tang YL, Sun H, et al
   Epidemiology, Clinical Features, and Molecular Basis of TTMV::RARA-driven Acute Promyelocytic Leukemia.
   Blood. 2025 Aug 14:blood.2025028674. doi: 10.1182/blood.2025028674.
   

   >> Share

   
   

   
   Cancer

5. WANG LL, Zhao P, Liu J, An ZY, et al
   Peritransplant lysine methyltransferase 2a-rearranged measurable residual disease dynamics as a prognostic marker in adult acute myeloid leukemia.
   Cancer. 2025;131:e70044.
   

   >> Share

   
   
6. ARORA S, Jen WY, Yilmaz M, Deshmukh I, et al
   Outcomes of patients with newly diagnosed acute myeloid leukemia with FLT3-tyrosine kinase domain mutations: Prognostic implications of NPM1 co-mutation.
   Cancer. 2025;131:e70032.
   

   >> Share

   
   

   
   Eur J Haematol

7. PALUMBO FE, Vetro C, Calafiore V, Duminuco A, et al
   Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow Involvement.
   Eur J Haematol. 2025 Aug 14. doi: 10.1111/ejh.70021.
   

   >> Share

   
   
8. STEIDEL E, Orhan E, Rasche M, Pigazzi M, et al
   Prognostic Value of Molecular Genetic Measurable Residual Disease (MRD) Monitoring in Pediatric Acute Myeloid Leukemia Expressing KMT2A::MLLT10.
   Eur J Haematol. 2025 Aug 13. doi: 10.1111/ejh.70019.
   

   >> Share

   
   

   
   Exp Hematol

9. WANG J, Xu L, Wang G, Wu W, et al
   ZC3H13 facilitates the progression of acute myeloid leukemia through m6A-FOXP1-mediated metabolic reprogramming.
   Exp Hematol. 2025 Aug 6:104862. doi: 10.1016/j.exphem.2025.104862.
   

   >> Share

   
   

   
   J Immunol

10. MU R, Hornick KM, Redekar N, Chen J, et al
    Activation and exhaustion of CD8 T cells in patients with chronic lymphocytic leukemia treated with ibrutinib and pembrolizumab.
    J Immunol. 2025 Aug 12:vkaf182. doi: 10.1093.
    

    >> Share

    
    

    
    J Pediatr Hematol Oncol

11. INDRASWARI BW, Supriyadi E, Kaspers GJL, Sitaresmi MN, et al
    Longitudinal Assessment of Health-Related Quality of Life in Childhood Acute Lymphoblastic Leukemia During Active Treatment in Indonesia.
    J Pediatr Hematol Oncol. 2025 Aug 8. doi: 10.1097/MPH.0000000000003097.
    

    >> Share

    
    

    
    Leuk Lymphoma

12. KARRAR O, Kantarjian H, Haddad FG, Azevedo RS, et al
    Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.
    Leuk Lymphoma. 2025 Aug 9:1-8. doi: 10.1080/10428194.2025.2542946.
    

    >> Share

    
    
13. MATSUI S, Nakahara W, Fukuda S, Hosoya M, et al
    Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient.
    Leuk Lymphoma. 2025 Aug 9:1-4. doi: 10.1080/10428194.2025.2544067.
    

    >> Share

    
    

    
    Leukemia

14. WU K, Liu H, Hu W, Liu Y, et al
    Clinically associated genomic landscape of pediatric non-Down Syndrome acute megakaryoblastic leukemia in Chinese patients.
    Leukemia. 2025 Aug 11. doi: 10.1038/s41375-025-02741.
    

    >> Share

    
    

    
    PLoS One

15. ABDUL RAZAK NH, Rasli NR, Mohamad Zamri N, Hamid A, et al
    Evaluation of organotin (IV) dithiocarbamate compounds as potential anti-leukemia agents towards CCRF-CEM (CCL-119) cell line: Cytotoxic, apoptotic, cell cycle and genotoxic study.
    PLoS One. 2025;20:e0329860.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share